Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
NCT06381284 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 215
Last updated 2025-03-25
Summary
This is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The main study objective is to evaluate the feasibility of a social media recruitment campaign tied to a participant reported symptom survey and self-administered physical assessment tool to influence undiagnosed participants to seek care for suspected Myasthenia Gravis (MG).
Conditions
- Myasthenia Gravis
- Neuromuscular Manifestations
- Neuromuscular Diseases
Interventions
- BEHAVIORAL
-
Social media recruitment
Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment
- BEHAVIORAL
-
Self-Assessment
Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups
- BEHAVIORAL
-
Follow-up
Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
Sponsors & Collaborators
-
UCB Pharma
collaborator INDUSTRY -
University of California, San Francisco
collaborator OTHER -
ZS Associates
lead INDUSTRY
Principal Investigators
-
Ananda Vishnu Pandurangadu, MD · ZS Associates
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-03-28
- Primary Completion
- 2025-03-03
- Completion
- 2025-03-03
Countries
- United States
Study Locations
More Related Trials
-
Disease-Modifying Treatments for Myasthenia Gravis
NCT03490539 ·Status: COMPLETED
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
NCT05564936 ·Status: RECRUITING ·Phase: NA
-
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
NCT03052751 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
NCT03772587 ·Status: COMPLETED ·Phase: PHASE2
-
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
NCT01828294 ·Status: TERMINATED ·Phase: PHASE1
-
Detecting Fatigue From Voice in Generalised Myasthenia Gravis
NCT07033559 ·Status: NOT_YET_RECRUITING
-
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
NCT05214612 ·Status: RECRUITING
-
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832 ·Status: RECRUITING
-
Biomarkers for Fatigue in Patients with Myasthenia Gravis
NCT06860347 ·Status: COMPLETED
-
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
NCT02565576 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Methotrexate in Myasthenia Gravis
NCT00814138 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
NCT03920293 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
NCT03971422 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
NCT06106672 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
NCT06909214 ·Status: RECRUITING ·Phase: PHASE4
-
Therapeutic Plasma Exchange in MG
NCT01927692 ·Status: COMPLETED
-
Efgartigimod for Consolidation Therapy in gMG
NCT07079020 ·Status: NOT_YET_RECRUITING
-
The Evaluation of Belimumab in Myasthenia Gravis (MG)
NCT01480596 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
NCT03896295 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Impact of Myasthenia Gravis in the Real World
NCT04176211 ·Status: COMPLETED
-
Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
NCT02609022 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT06617741 ·Status: RECRUITING
-
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
NCT06860633 ·Status: RECRUITING ·Phase: PHASE4